KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to -$93.1 million.

  • CRISPR Therapeutics AG's Free Cash Flow fell 8508.5% to -$93.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$345.9 million, marking a year-over-year decrease of 13910.7%. This contributed to the annual value of -$345.9 million for FY2025, which is 13910.7% down from last year.
  • As of Q4 2025, CRISPR Therapeutics AG's Free Cash Flow stood at -$93.1 million, which was down 8508.5% from -$84.7 million recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Free Cash Flow registered a high of $780.4 million during Q2 2021, and its lowest value of -$151.6 million during Q2 2022.
  • In the last 5 years, CRISPR Therapeutics AG's Free Cash Flow had a median value of -$96.6 million in 2023 and averaged -$41.8 million.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Free Cash Flow soared by 247311.76% in 2021 and then plummeted by 15523.42% in 2024.
  • CRISPR Therapeutics AG's Free Cash Flow (Quarter) stood at -$95.2 million in 2021, then fell by 25.52% to -$119.5 million in 2022, then increased by 19.0% to -$96.8 million in 2023, then soared by 48.06% to -$50.3 million in 2024, then crashed by 85.09% to -$93.1 million in 2025.
  • Its last three reported values are -$93.1 million in Q4 2025, -$84.7 million for Q3 2025, and -$114.0 million during Q2 2025.